8-KMaterial Agreements

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Feb 7, 2011)

Filed February 7, 2011For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on February 7, 2011, reporting a material definitive agreement. The company's wholly-owned subsidiary, Gilead Sciences Limited (GSL), entered into an addendum to its existing manufacturing supply agreement with PharmaChem Technologies (Grand Bahama) Ltd. (PharmaChem). This addendum is significant as it extends the supply of bulk tenofovir disoproxil fumarate, a key active pharmaceutical ingredient for Gilead's important HIV medications such as Viread®, Truvada®, and Atripla®. The extension of the supply agreement from December 31, 2012, to December 31, 2016, with an option for further extension, provides greater long-term supply chain certainty for these critical drugs. Investors should note the commitment to minimum purchase obligations and pricing projections for the extended period, which suggests continued strategic importance and expected demand for these products.

Key Highlights

  • 1Gilead's subsidiary, GSL, entered into an addendum to a material definitive agreement with PharmaChem.
  • 2The agreement concerns the manufacturing and supply of bulk tenofovir disoproxil fumarate, a key ingredient in Gilead's HIV treatments.
  • 3The term of the supply agreement is extended from December 31, 2012, to December 31, 2016.
  • 4GSL has an option to further extend the agreement to December 31, 2017.
  • 5The addendum includes GSL's minimum total purchase obligations and corresponding pricing projections for the extended period.
  • 6This ensures a continued supply chain for essential HIV medications like Viread®, Truvada®, and Atripla®.

Frequently Asked Questions

The main purpose of this 8-K filing is to report a material definitive agreement. Specifically, it details an addendum to an existing supply agreement between Gilead's subsidiary and PharmaChem for the manufacturing of a key pharmaceutical ingredient.

The extended supply agreement for tenofovir disoproxil fumarate will impact Gilead's HIV medications: Viread® (tenofovir disoproxil fumarate as a single agent), Truvada® (tenofovir disoproxil fumarate and emtricitabine), and Atripla® (tenofovir disoproxil fumarate, emtricitabine, and efavirenz).

Extending the supply agreement provides Gilead with long-term certainty for the supply of a critical active pharmaceutical ingredient. This is important for ensuring the consistent availability of its leading HIV treatments to patients and for maintaining its market position in this therapeutic area.

The addendum includes GSL's minimum total purchase obligations and corresponding pricing projections for the extension period. While specific financial figures are not disclosed in this summary, these terms indicate a commitment from Gilead to purchase a certain volume of the ingredient at pre-determined pricing, suggesting continued investment and expected revenue from the associated products.